tradingkey.logo

PharmaCyte Biotech Inc

PMCB
View Detailed Chart

0.980USD

+0.009+0.96%
Close 09/19, 16:00ETQuotes delayed by 15 min
6.66MMarket Cap
LossP/E TTM

PharmaCyte Biotech Inc

0.980

+0.009+0.96%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.96%

5 Days

-5.77%

1 Month

-2.83%

6 Months

-41.67%

Year to Date

-37.58%

1 Year

-52.20%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
204 / 506
Overall Ranking
329 / 4720
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD 23.36M.%!(EXTRA int=2)
Fairly Valued
The company’s latest PE is 0.31, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.28M shares, decreasing 28.93% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 194.45K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 4.02.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
Ticker SymbolPMCB
CompanyPharmaCyte Biotech Inc
CEOMr. Joshua N. (Josh) Silverman
Websitehttps://pharmacyte.com/
KeyAI